BC
NKTR icon

Brinker Capital’s Nektar Therapeutics NKTR Stock Holding History

Brinker Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,373
Closed -$2.02M – 978
2019
Q3 		$2.02M Buy
+7,373
New +$2.7M 0.07% 295
2019
Q2 		– Sell
-3,521
Closed -$1.77M – 956
2019
Q1 		$1.77M Buy
3,521
+845
+32% +$501K 0.07% 310
2018
Q4 		$1.32M Sell
2,676
-246
-8% -$148K 0.06% 327
2018
Q3 		$2.67M Buy
2,922
+707
+32% +$603K 0.1% 214
2018
Q2 		$1.62M Buy
2,215
+1,462
+194% +$1.69M 0.06% 339
2018
Q1 		$1.2M Sell
753
-617
-45% -$795K 0.05% 419
2017
Q4 		$1.23M Sell
1,370
-1,615
-54% -$955K 0.05% 367
2017
Q3 		$1.07M Sell
2,985
-11
-0.4% -$3.44K 0.04% 391
2017
Q2 		$879K Buy
2,996
+43
+1% +$12.4K 0.04% 396
2017
Q1 		$1.04M Buy
+2,953
New +$664K 0.05% 359

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Brinker Capital's NKTR Position: Q4 2019 in Review

Brinker Capital sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 7,373 shares — an estimated $2.02M sold.

Brinker Capital first reported a position in NKTR in Q1 2017 and held it in 10 quarters. The position peaked at $2.67M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Brinker Capital reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Brinker Capital sold 7,373 Nektar Therapeutics shares in Q4 2019, an estimated $2.02M.
  • Brinker Capital first reported a position in Nektar Therapeutics in Q1 2017 and held it in 10 quarters.
  • Brinker Capital's Nektar Therapeutics position peaked at $2.67M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Brinker Capital's 13F filing for Q4 2019, filed 18 Feb 2020.